Literature DB >> 34214829

Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4+ T cells in the draining lymph nodes of breast cancer.

Atri Ghods1, Fereshteh Mehdipour2, Mahmoud Shariat3, Abdol-Rasoul Talei4, Abbas Ghaderi5.   

Abstract

Tumor Necrosis Factor Receptor 2 (TNFR2) is one of the receptors of TNF-α, which is expressed on various cell types. TNFR2 signaling has a balancing role between regulatory and effector functions of T cells. Herein, we investigated the expression of TNFR2 on regulatory T cells (Tregs) and non-Tregs in breast tumor-draining lymph nodes. Mononuclear cells were isolated from 16 axillary lymph nodes, and the expressions of TNFR2, Foxp3 and CD25 were assessed in CD4+ T cells by flow cytometry. Our results showed that the majority of TNFR2+CD4+ T cells were Foxp3-CD25-. However, the percentage of TNFR2+ cells was significantly higher in Foxp3+CD25+CD4+ Tregs compared to Foxp3-CD25-CD4+, Foxp3+CD25-CD4+, and Foxp3-CD25+CD4+ T cell subsets. Among these subsets, Foxp3+CD25+TNFR2+CD4+ T cells were found to have the highest intensity of TNFR2 expression. The intensity of Foxp3 expression in Foxp3+CD25+TNFR2+CD4+ Treg cells was significantly higher than in their TNFR2- counterpart. Collectively, we showed that most of TNFR2+CD4+ T lymphocytes were Foxp3-CD25-, while the majority of Foxp3+CD25+CD4+ Tregs were TNFR2+, and they expressed TNFR2 with the highest intensity. This report highlights the importance of TNFR2 expression on Tregs and paves the way for further investigation of the effects of TNF-α on the suppressive activity of Tregs in the tumor microenvironment.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Regulatory T cells; TNFR2; Tumor-draining lymph nodes

Year:  2021        PMID: 34214829     DOI: 10.1016/j.molimm.2021.06.013

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  4 in total

Review 1.  Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy.

Authors:  Juliane Medler; Kirstin Kucka; Harald Wajant
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

Review 2.  Targeting TNFR2 in Cancer: All Roads Lead to Rome.

Authors:  Jingchao Bai; Bowen Ding; Hui Li
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

3.  Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3+ T regulatory cells in colorectal cancer.

Authors:  Bing Yan; Jianmei Xiong; Qianwen Ye; Tianhui Xue; Jia Xiang; Mingyue Xu; Fang Li; Wei Wen
Journal:  BMC Gastroenterol       Date:  2022-03-16       Impact factor: 3.067

4.  Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer.

Authors:  Kumiko Hayashi; Daichi Nogawa; Maki Kobayashi; Ayaka Asakawa; Yae Ohata; Shota Kitagawa; Kazuishi Kubota; Hisashi Takahashi; Miyuki Yamada; Goshi Oda; Tsuyoshi Nakagawa; Hiroyuki Uetake; Iichiroh Onishi; Yuko Kinowaki; Morito Kurata; Masanobu Kitagawa; Kouhei Yamamoto
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.